Author:
Liberator, MD Cole,Heymann, MD Jonas,Saqi, MD, MBA Anjali,Shu, MD` Catherine,Crapanzano, MD John,Bulman, MD William
Abstract
Immunotherapy has emerged as a potent tool in the treatment of lung cancer, particularly in patients with advanced disease. Multiple drugs are now available which cause an anti-tumor immune response by blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand, PDL1, which is expressed in some tumors. This review explores the role of immunotherapy and the practical implications of testing for PD-L1 in patients with malignant pleural effusion.
Publisher
International Society of Pleural Diseases
Reference124 articles.
1. 1. Coley WB, MD. The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas:
2. With a Report of Ten Original Cases. Clinical Orthopaedics & Related Research January. 1991;262:3-11.
3. 2. Management of Malignant Pleural Effusions. 2000;162(5):1987-2001.
4. 3. Rodriguez-Panadero F, Naranjo FB, Mejias JL. Pleural metastatic tumours and effusions. Frequency and
5. pathogenic mechanisms in a post-mortem series. European Respiratory Journal. 1989;2(4):366-369.